Top

Published in:

01-09-2011 | Research

Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in Breast Cancer Patients

Authors: Lidija Beketic-Oreskovic, Petar Ozretic, Zahid N. Rabbani, Isabel L. Jackson, Bozena Sarcevic, Sonja Levanat, Petra Maric, Ivan Babic, Zeljko Vujaskovic

Published in: Pathology & Oncology Research | Issue 3/2011

Abstract

The aim of this study was to examine the prognostic significance of carbonic anhydrase IX (CA-IX), an endogenous marker for tumor hypoxia; endoglin (CD105), a proliferation-associated and hypoxia-inducible glycoprotein and 8-hydroxy-2′-deoxyguanosine (8-OHdG), an oxidative DNA lesion, in breast cancer patients. Immunohistochemical expressions of CA-IX, CD105 and 8-OHdG, analyzed on paraffin-embedded tumor tissues from forty female breast cancer patients, were used to assess their prognostic implication on overall survival (OS) and relapse-free survival (RFS). Patients with high CA-IX expression (above cut-off value) had a higher occurrence of relapse (P = 0.002). High CA-IX expression was significantly associated with shorter RFS (P < 0.001, hazard ratio (HR) 0.21) and shorter OS (P < 0.001, HR 0.19). Lymph node negative patients with high CA-IX expression had worse RFS (P = 0.031, HR 0.14) and OS (P = 0.005, HR 0.05). Patients with grade I&II tumors and high CA-IX expression showed shorter RFS (P = 0.028, HR 0.28) and OS (P = 0.008, HR 0.20). Worse OS (P = 0.046, HR 0.28) was found in subgroup of patients with grade II tumors and high CA-IX expression. Among all three markers, only high CA-IX expression was strong independent prognostic indicator for shorter OS (HR 4.14, 95% CI 1.28–13.35, P = 0.018) and shorter RFS (HR 3.99, 95% CI 1.38–11.59, P = 0.011). Elevated expression of CA-IX was an independent prognostic factor for decreased RFS and OS and a significant marker for tumor aggressiveness. CD105 had week prognostic value; whereas, 8-OHdG, in this study, did not provide sufficient evidence as a prognostic indicator in breast cancer patients.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71–96PubMedCrossRef

Fisher B, Bauer M, Wickerham DL et al (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52:1551–1557PubMedCrossRef

Davis BW, Gelber RD, Goldhirsch A (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef

Koscielny S, Tubiana M, Lê MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715PubMedCrossRef

Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25PubMed

Leek RD, Landers RJ, Harris AL et al (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79:991–995PubMedCrossRef

Mueller-Klieser W, Freyer JP, Sutherland RM (1983) Evidence for a major role of glucose in controlling development of necrosis in EMT6/Ro multicell tumor spheroids. Adv Exp Med Biol 159:487–495PubMed

Parliament MB, Franko AJ, Allalunis-Turner MJ et al (1997) Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer 75:311–318PubMedCrossRef

Ramanujan S, Koenig GC, Padera TP et al (2000) Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60:1442–1448PubMed

10.

Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107:1053–1062PubMedCrossRef

11.

Vaupel P, Schlenger K, Knoop C et al (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O₂ tension measurements. Cancer Res 51:3316–3322PubMed

12.

Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMedCrossRef

13.

Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47PubMedCrossRef

14.

Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedCrossRef

15.

Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104–8109PubMedCrossRef

16.

Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed

17.

Wykoff CC, Beasley NJ, Watson PH et al (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083PubMed

18.

Chia SK, Wykoff CC, Watson PH et al (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19:3660–3668PubMed

19.

Span PN, Bussink J, Manders P et al (2003) Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89:271–276PubMedCrossRef

20.

Hussain SA, Ganesan R, Reynolds G et al (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96:104–109PubMedCrossRef

21.

Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399PubMed

22.

Olive PL, Aquino-Parsons C, MacPhail SH et al (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:8924–8929PubMed

23.

Giatromanolaki A, Koukourakis MI, Sivridis E et al (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61:7992–7998PubMed

24.

Kim SJ, Rabbani ZN, Vollmer RT et al (2004) Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10:7925–7933PubMedCrossRef

25.

Kim SJ, Rabbani ZN, Dewhirst MW et al (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335PubMedCrossRef

26.

Hui EP, Chan AT, Pezzella F et al (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595–2604PubMed

27.

Liao SY, Aurelio ON, Jan K et al (1997) Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57:2827–2831PubMed

28.

McKiernan JM, Buttyan R, Bander NH et al (1997) Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57:2362–2365PubMed

29.

Colpaert CG, Vermeulen PB, Fox SB et al (2003) The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 81:137–147PubMedCrossRef

30.

Vleugel MM, Greijer AE, Shvarts A et al (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58:172–177PubMedCrossRef

31.

Kumar P, Wang JM, Bernabeu C (1996) CD105 and angiogenesis. J Pathol 178:363–366PubMedCrossRef

32.

Fonsatti E, Del Vecchio L, Altomonte M et al (2001) Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188:1–7PubMedCrossRef

33.

Kumar S, Ghellal A, Li C et al (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856–861PubMed

34.

Dales JP, Garcia S, Bonnier P et al (2003) CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 119:374–380PubMedCrossRef

35.

Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21:361–370PubMedCrossRef

36.

Wu LL, Chiou CC, Chang PY et al (2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 339:1–9PubMedCrossRef

37.

Nagashima M, Tsuda H, Takenoshita S et al (1995) 8-hydroxydeoxyguanosine levels in DNA of human breast cancer are not significantly different from those of non-cancerous breast tissues by the HPLC-ECD method. Cancer Lett 90:157–162PubMedCrossRef

38.

Musarrat J, Arezina-Wilson J, Wani AA (1996) Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer 32A:1209–1214PubMedCrossRef

39.

Kuo HW, Chou SY, Hu TW et al (2007) Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients. Mutat Res 631:62–68PubMed

40.

Himmetoglu S, Dincer Y, Ersoy YE et al (2009) DNA oxidation and antioxidant status in breast cancer. J Investig Med 57:720–723PubMed

41.

Karihtala P, Winqvist R, Syväoja JE et al (2006) Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur J Cancer 42:2653–2659PubMedCrossRef

42.

Wang X, Ryter SW, Dai C et al (2003) Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway. J Biol Chem 278:29184–29191PubMedCrossRef

43.

Liao SY, Darcy KM, Randall LM et al (2010) Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116:452–458PubMedCrossRef

44.

Chandel NS, McClintock DS, Feliciano CE et al (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O₂ sensing. J Biol Chem 275:25130–25138PubMedCrossRef

45.

Klimova T, Chandel NS (2008) Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 15:660–666PubMedCrossRef

46.

Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978PubMed

47.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

48.

Elledge RM, McGuire WL (1993) Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 44:201–210PubMedCrossRef

49.

Rosen PR, Groshen S, Saigo PE et al (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355–366PubMed

50.

Honda M, Yamada Y, Tomonaga M et al (2000) Correlation of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk Res 24:461–468PubMedCrossRef

Title: Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in Breast Cancer Patients
Authors: Lidija Beketic-Oreskovic
Petar Ozretic
Zahid N. Rabbani
Isabel L. Jackson
Bozena Sarcevic
Sonja Levanat
Petra Maric
Ivan Babic
Zeljko Vujaskovic
Publication date: 01-09-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9355-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Downregulated Expression of Inhibitor of Growth 4 (ING4) in Advanced Colorectal Cancers: A Non-Randomized Experimental Study

Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival

Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

Divergent Squamous Differentiation in Upper Urothelial Carcinoma—Comparative Clinicopathological and Molecular Study

Expression of CDX2 and Hepatocyte Antigen in Benign and Malignant Lesions of Gallbladder and Its Correlation with Histopathologic Type and Clinical Outcome

Immunoexpression of SALL4 in Wilms Tumors and Developing Kidney

Keynote webinar | Spotlight on antibody–drug conjugates in cancer